Latest News

Investors may be wondering whether Palvella Therapeutics at around US$120 a share is still offering value, or if most of the easy gains are already on the table. The stock is up 5.7% over the last 7 days and 20.1% year to date, with a very strong 333.7% return over the past year that may indicate shifting expectations and risk perceptions. Recent attention around Palvella Therapeutics has focused on its position in the biotech space and how the market is reassessing smaller, high potential...

Telesat (NasdaqGS:TSAT) disclosed that its auditor raised substantial doubt about the company’s ability to continue as a going concern in its latest Form 20-F filing. The company also announced plans to add military Ka-band spectrum to its Lightspeed low Earth orbit satellite constellation to support defense requirements. Both developments point to rising pressure on Telesat’s funding profile alongside a clearer push toward government and defense users. Telesat operates in satellite...

Setting the scene: Blaize Holdings's FY 2025 earnings snapshot Blaize Holdings (BZAI) just closed FY 2025 with fourth quarter revenue of US$23.8 million and basic EPS of US$0.03 loss, against trailing twelve month revenue of US$38.6 million and EPS of US$1.98 loss, alongside very large reported year over year revenue growth of 2,386%. The company has seen quarterly revenue move from US$0.001 million in Q4 FY 2024 to US$23.8 million in Q4 FY 2025. Over that span, EPS has ranged from US$1.61...

Wondering if Live Nation Entertainment at around US$154.92 a share still offers value or if most of the upside is already reflected in the price? This breakdown will help you frame that question clearly. The stock has had a mixed recent run, with a 1% decline over the last week and a 2.1% decline over the last month. It is still sitting on a 6.6% year to date gain and a 22.2% return over the last year, alongside a 125.8% return over three years and an 83.0% return over five years. Recent...

Amidst a cautious atmosphere on the ASX, driven by geopolitical uncertainties, Australian shares have seen modest gains. In such a climate, investors often look beyond established giants to explore opportunities in lesser-known sectors. Penny stocks, while an older term, continue to represent smaller or newer companies with potential for growth and value; focusing on those with solid financials can uncover promising investment opportunities.

TransAlta Corporation recently held its 2026 Investor Day, outlining plans to pursue value-accretive M&A, advance legacy site projects like Centralia and Alberta data centers, and build out a high-quality development pipeline to align with an evolving energy landscape. An interesting angle from the event is TransAlta’s explicit focus on data center-related electricity demand, highlighting how legacy sites may be repurposed to capture this emerging load. Now we’ll examine how TransAlta’s...

Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Hitachi...

Even though Inspur Digital Enterprise Technology Limited ( HKG:596 ) has fallen by 10% over the past week , insiders...

A shareholder proposal giving investors the right to act by written consent has been submitted at BorgWarner ahead of the upcoming annual meeting. BorgWarner's board has recommended a vote against the proposal, creating a clear split between management and the proponent. The outcome could influence how NYSE:BWA shareholders exercise governance rights between annual meetings. BorgWarner, trading as NYSE:BWA, is entering the annual meeting with governance in focus and a share price of $56.12...

Newron Pharmaceuticals (SWX:NWRN) has opened FY 2025 with first half revenue of €11.9 million and a basic EPS loss of €0.00, setting a cautious tone against a share price of CHF 14.64. Over recent periods, the company has seen revenue move from €3.4 million in H1 2024 to €48.0 million in H2 2024 and then to €11.9 million in H1 2025. Basic EPS has shifted from a loss of €0.51 in H1 2024 to a profit of €1.37 in H2 2024 and back to a marginal loss in the latest half, leaving investors focused on...

AI powered autonomous agents such as Anthropic's Claude are emerging as cross platform tools that can handle complex workflows typically managed by enterprise software. Investors are starting to question how this could affect the role of traditional application layer providers, including Manhattan Associates (NasdaqGS:MANH), particularly around pricing power and profitability. This development has recently drawn more attention, yet it has not been a core focus of recent coverage that...

Q3 2026 Earnings Snapshot Cintas (CTAS) has just reported Q3 2026 results with quarterly revenue of about US$2.8b and basic EPS of US$1.23, giving investors a fresh read on how the business is tracking this year. Over recent quarters the company has seen revenue move from US$2.50b in Q1 2025 to US$2.80b in Q2 2026, while basic EPS has shifted from US$1.12 to US$1.23, with trailing twelve month net profit margins around 17.5% helping to frame the quality of those earnings. See our full...

Daktronics (DAKT) is back in the spotlight after announcing three fresh major league baseball projects, including a new Mariners Fire TV outfield board in Seattle and large center field displays in Phoenix and Chicago. See our latest analysis for Daktronics. The recent major league baseball wins sit against a mixed share price backdrop, with a 7 day share price return of 5.88%, a 30 day share price return of 22.11% and a 1 year total shareholder return of 69.73%. This indicates that longer...

Wondering if Alkermes at around US$29.37 is a bargain or already pricing in its prospects? This article walks through how the numbers stack up so you can judge the value for yourself. The stock has returned 8.0% over the last 7 days, while the 30 day return is an 8.8% decline, with year to date performance at 3.9% and a 12.8% decline over the past year. Recent coverage has focused on Alkermes as a listed US pharmaceuticals and biotech name, putting attention on how investors are weighing its...

Epsilon Energy (EPSN) has just posted its FY 2025 numbers with third quarter revenue of about US$9.0 million and basic EPS of US$0.05, set against trailing twelve month revenue of US$45.7 million and EPS of US$0.27 that came alongside 11.2% earnings growth and a trailing net margin of 12.9% compared with 17% a year earlier. Over recent quarters the company has seen revenue move from US$7.3 million in Q2 2024 to US$16.2 million in Q1 2025, then to US$9.0 million in Q3 2025. Quarterly EPS has...

BioStem Technologies (OTCPK:BSEM) appointed Jodi Ungrodt as a new member of its Board of Directors and Chair of the Audit Committee. The company completed the acquisition of BioTissue Holdings Inc.'s surgical and wound assets, including a national sales force. The transaction expands BioStem's commercial reach into hospital settings and broadens its product portfolio. BioStem Technologies, trading at $4.92, sits at an interesting point in its share price history, with a 25.9% return year to...

If you are wondering whether AMETEK at around US$215 per share looks expensive or offers value, it is helpful to separate price action from underlying worth. The stock has seen mixed moves recently, with a 1.2% gain over the last 7 days, a 7.0% decline over 30 days, and returns of 3.0% year to date, 22.5% over the past year, 54.4% over 3 years, and 74.2% over 5 years. These moves come alongside a steady stream of company updates and industry commentary that keep AMETEK on many investors'...

Zhihu (NYSE:ZH) has posted a mixed FY 2025 update, with Q3 revenue at C¥658.9 million and basic EPS of C¥0.58 loss per share, while trailing 12 month figures show revenue of C¥2.97 billion and basic EPS of C¥1.25. Over recent quarters, revenue has shifted from C¥933.8 million in Q2 2024 to C¥859.2 million in Q4 2024, then to C¥716.9 million in Q2 2025 and C¥658.9 million in Q3 2025. Net income moved from a C¥82.7 million loss in Q2 2024 to a C¥72.5 million profit in Q2 2025, before a C¥46.7...

Why Flywire is On Investors’ Radar Today Flywire (FLYW) has been drawing attention after a stretch where its share price showed a mix of gains over the past month and declines across the past 3 months and year to date. Investors are weighing how this recent trading pattern lines up with the company’s fundamentals and global payments footprint. See our latest analysis for Flywire. With the share price at $12.40, Flywire’s recent 16.5% 1 month share price return contrasts with its 14.3% 3 month...

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...

Vt Holdings Co.,Ltd. ( TSE:7593 ) stock is about to trade ex-dividend in three days. The ex-dividend date is usually...

Glass House Brands (OTCPK:GLAS.F) has just posted a mixed FY 2025 picture, with Q3 revenue of US$38.4 million and a basic EPS loss of US$0.19, set against trailing 12 month revenue of US$196.2 million and a basic EPS loss of US$0.23. Over recent quarters, the company has seen revenue range from US$53.0 million in Q4 2024 to US$59.9 million in Q2 2025, while basic EPS has swung between a profit of US$0.10 in Q4 2024 and a loss of US$0.19 in Q3 2025. This keeps the focus firmly on how...

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...

Inspire Medical Systems (NYSE:INSP) has put forward a proposal to amend its Certificate of Incorporation. Shareholders are scheduled to vote on the amendment at the upcoming annual general meeting. The change targets the company’s core governance framework, which may influence how future decisions are approved and overseen. The vote comes at a time when Inspire Medical Systems shares trade around $51.41, with returns showing an 8.8% decline over the past week and 11.8% over the past month...